In a landmark achievement that resonates beyond its borders, Uganda has positioned itself at the forefront of global medical innovation, as the United States Patent and Trademark Office (USPTO) has formally accepted two groundbreaking vaccine patent applications by Dr. Mathias Magoola, a Ugandan pharmacist and founder of Dei BioPharma Limited.
These innovations, a universal mRNA cancer vaccine and an ultra-affordable scFv biologic therapy, are set not only to revolutionise disease treatment but also to shatter the persistent barriers of accessibility and affordability in healthcare worldwide.
“These innovations, whose patent applications were both accepted by USPTO on July 21, are poised to reshape the treatment landscape for cancer and immune diseases while breaking down barriers to access and affordability,” Dr. Magoola stated in a press briefing, underscoring the humanitarian ethos driving his scientific pursuits.
This momentous approval adds to Dr. Magoola’s impressive portfolio of over 100 patents filed in the U.S., spanning treatments and vaccines for a myriad of diseases, including cancer, HIV, Alzheimer’s, Malaria, Tuberculosis, and diabetes.
His work unequivocally establishes Uganda as a budding hub of advanced biotechnological research and development.
The Universal mRNA Cancer Vaccine
The first patented platform is a universal messenger RNA (mRNA) cancer vaccine designed to transform “cold” (immune-invisible) tumours into “hot” (immune-responsive) targets.
Unlike conventional cancer vaccines that often require patient-specific customisation, this pioneering vaccine utilises non-tumour-specific antigens compressed in lipid nanoparticles.
This ingenious approach stimulates powerful Type-I interferon responses, triggering widespread immune system activation against cancerous cells.
According to Dr. Magoola, Dei BioPharma’s preclinical trials have yielded remarkable efficacy, demonstrating complete tumour regression and up to 90% protection against recurrence. The vaccine’s ability to induce “epitope spreading” further empowers the immune system to recognise multiple tumour markers simultaneously, showcasing a strong synergy with existing checkpoint inhibitors, such as anti-PD-1 therapies.
“This innovation, protected by a patent filed in the US, positions Dei BioPharma as a global leader in immune programming and cancer immunotherapy,” Dr. Magoola affirmed, highlighting the strategic global standing this breakthrough confers upon a Ugandan-led enterprise.
Ultra-Affordable Biologics: Democratising Immune Therapies
The second patented platform introduces a next-generation single-chain variable fragment (scFv) biologic targeting IL-23p19. This cytokine, Dr. Magoola noted, is associated with severe immune diseases and is currently targeted by exorbitantly priced drugs such as Skyrizi and Tremfya.
Dei BioPharma’s engineered scFv offers a revolutionary alternative:
Compact and Cost-Efficient: Unlike full-sized monoclonal antibodies, this biologic is significantly smaller and designed for cost-effective production.
Enhanced Delivery: Fused with albumin or transferrin for extended half-life, it allows for multiple administration routes, including inhalers, patches, nasal sprays, and topical creams, making it highly adaptable for diverse clinical settings and patient needs.
Radical Cost Reduction: Manufactured in microbial systems, this biologic slashes production costs by up to 80%, promising to make life-saving immune therapies accessible to a far broader global population. Its small molecular size also significantly improves tissue penetration.
With this patent, Dei BioPharma is not merely introducing a new drug; it’s ushering in a new class of accessible biologics that could fundamentally replace some of the world’s most expensive immune therapies, thereby levelling the playing field for healthcare access.
Uganda’s Global Footprint in Health Innovation
Dr. Magoola summarised the profound implications of these patents, saying, “These patents are not just scientific achievements, they are moral declarations. We are abolishing the myth that cures belong only to the rich. This is the future of medicine; scientifically advanced, globally accessible, and deeply human.”
This dual patent acceptance by the USPTO, one of the world’s most rigorous patenting authorities, unequivocally positions Uganda on the global map of advanced biomedical research and development. It signifies:
It validates Uganda’s intellectual capital and research capabilities on an international stage.
By focusing on cost-effective innovations, Uganda, through Dei BioPharma, is leading the charge in democratising access to cutting-edge medical treatments, particularly for low- and middle-income countries that bear a disproportionate burden of disease.
This achievement serves as a powerful inspiration and potential catalyst for further investment and development within Uganda’s nascent biopharmaceutical sector, fostering a knowledge-based economy.
Dr. Magoola’s achievements, culminating in these significant U.S. patents, are a powerful testament to Uganda’s growing influence in shaping the future of global medicine, proving that groundbreaking scientific innovation can indeed emerge from Africa to benefit all of humanity.